Shikonin sensitizes wild-type EGFR NSCLC cells to erlotinib and gefitinib therapy

As patients with non-small cell lung cancer (NSCLC) and wild-type epidermal growth factor receptor (EGFR) are resistant to treatment with erlotinib or gefitinib, potential chemosensitizers are required to potentiate wild-type EGFR NSCLC cells to erlotinib/gefitinib treatment. The present study repor...

Full description

Saved in:
Bibliographic Details
Published in:Mol Med Rep
Main Authors: Li, Yang-Ling, Hu, Xiu, Li, Qing-Yu, Wang, Fei, Zhang, Bo, Ding, Ke, Tan, Bi-Qin, Lin, Neng-Ming, Zhang, Chong
Format: Artigo
Language:Inglês
Published: D.A. Spandidos 2018
Subjects:
Articles
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6131653/
https://ncbi.nlm.nih.gov/pubmed/30106133
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/mmr.2018.9347
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items